Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons

Psychopharmacology

Volumn 225, Issue 3, 2013, Pages 637-646

  Goodwin, Amy K ^a   Kaminski, Barbara J ^a   Weerts, Elise M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse liability; Cocaine; Drug abuse; Gamma hydroxybutyrate; Operant behavior; Reinforcement; Self administration; Zolpidem

Indexed keywords

1,4 BUTANEDIOL; COCAINE; GAMMA BUTYROLACTONE; ZOLPIDEM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BABOON; CONTROLLED STUDY; DRUG ABUSE; DRUG SELF ADMINISTRATION; INJECTION; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RETCHING; TREMOR; VOMITING;

4-BUTYROLACTONE; ANIMALS; BUTYLENE GLYCOLS; COCAINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDROXYBUTYRATES; INJECTIONS, INTRAVENOUS; MALE; PAPIO; PRODRUGS; REINFORCEMENT (PSYCHOLOGY); REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 84873730712     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2851-5     Document Type: Article

References (50)

1. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S (2011) An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 3:560-8
2. Arena C, Fung HL (1980) Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma- butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 69:356-358
3. Ator NA (2000) Zaleplon and triazolam: drug discrimination, plasma levels and self-administration in baboons. Drug Alcohol Depend 61:55-68
4. Ator NA (2002) Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons. Psychopharmacology (Berl) 163:477-487
5. Beardsley P, Balster R, Harris L (1996) Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacology (Berl) 127:315-322
6. Bell J, Collins R (2011) Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 106:442-447
7. Carter LP, Pardi D, Gorsline J, Griffiths RR (2009) Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 104:1-10
8. CDC (1999) Adverse events associated with ingestion of gamma-butyrolactone: Minnesota, New Mexico, and Texas, 1998-1999. U.S. Government Printing Office, Atlanta, pp 137-140
9. Couper FJ, Thatcher JE, Logan BK (2004) Suspected GHB overdoses in the emergency department. J Anal Toxicol 28:481-484
10. DEA (2000) Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule. Fed Regist 65:21645-21647
11. Duer WC, Byers KL, Martin JV (2001) Application of a convenient extraction procedure to analyze gamma-hydroxybutyric acid in fatalities involving gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol. J Anal Toxicol 25:576-582
12. ECDD WHO (2012) Gamma-hydroxybutyric acide (GHB) critical review report. In: World Health Organization (WHO), 35th Expert Committee on Drug Dependence (ECDD): Hammamet, Tunisia
13. EMCDDA (2008) GHB and its precursor GBL: an emerging trend case study. European Monitoring Centre for Drugs and Drug Addiction thematic paper. EMCDDA, Lisbon
14. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (1997) Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92:89-96
15. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE (2000) Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 20:263-269
16. Goodwin AK, Froestl W, Weerts EM (2005) Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons. Psychopharmacology (Berl) 180:342-351
17. Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM, Weerts EM (2006) Chronic intragastric admistration of gamma-butyrolactone (GBL) produces physical dependence in baboons. Psychopharmacology 189:71-82
18. Goodwin AK, Brown PR, Jansen EE, Jakobs C, Gibson KM, Weerts EM (2009) Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 204:465-476
19. Goodwin AK, Kaminski BJ, Griffiths RR, Ator NA, Weerts EM (2011) Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend 114:217-224
20. Griffiths RR, Weerts EM (1997) Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1-37
21. Griffiths R, Lukas S, Bradford L, Brady J, Snell J (1981) Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 75:101-109
22. Griffiths RR, Sannerud CA, Ator NA, Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260:1199-1208
23. Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45:330-340
24. Ingels M, Rangan C, Bellezzo J, Clark RF (2000) Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 19:47-50
25. Irwin RD (1996) NTP Summary report on the mtabolism, disposition, and toxicity of 1,4-butanediol (CAS No 110-63-4). Natl Toxicol Prog Toxicity Rep Ser 54:1-28
26. Jones AL (2010) Legal 'highs' available through the Internet-implications and solutions? QJM 103:535-536
27. Karila L, Reynaud M (2010) GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 3:552-9
28. Lukas SE, Griffiths RR, Bradford LD, Brady JV, Daley L (1982) A tethering system for intravenous and intragastric drug administration in the baboon. Pharmacol Biochem Behav 17:823-829
29. McDonough M, Kennedy N, Glasper A, Bearn J (2004) Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 75:3-9
30. McMahon LR, Coop A, France CP, Winger G, Woolverton WL (2003) Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. Eur J Pharmacol 466:113-120
31. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R (2001) Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 10:232-241
32. Palmer R (2004) Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate. Toxicol Rev 23:21-31
33. Roth RH, Giarman NJ (1965) Preliminary report on the metabolism of g-butyrolactone and g-hydroxybutyric acid. Biochem Pharmacol 14:177-178
34. Rowlett JK, Lelas S (2007) Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses. Exp Clin Psychopharmacol 15:328-337
35. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50:458-470
36. Schneir AB, Ly BT, Clark RF (2001) A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 21:31-33
37. Shannon M, Quang LS (2000) Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 16:435-440
38. Snead OC, Furner R, Liu CC (1989) In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem Pharmacol 38:4375-4380
39. Stein LA, Lebeau R, Clair M, Martin R, Bryant M, Storti S, Monti P (2011) A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 20:30-39
40. Teter CJ, Guthrie SK (2001) A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 21:1486-1513
41. Vree TB, van Dalen R, Kleijn VD, Gimbrere JSF (1978) Pharmacokinetics of 1,4-butanediol and 4-hydroxybutyric acid in man, rhesus monkey, and dog. Anasthesiol Intensivmed Notfallmed Schmerzther 110:66-73
42. Weerts EM, Griffiths RR (1998) Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav Pharmacol 9:285-297
43. Weerts EM, Ator NA, Grech DM, Griffiths RR (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther 285:41-53
44. Weerts EM, Ator NA, Griffiths RR (1999) Comparison of the intravenous reinforcing effects of propofol and methohexital in baboons. Drug and Alcohol Depend 57:51-60
45. Weerts E, Goodwin A, Griffiths R, Brown P, Froestl W, Jakobs C, Gibson K (2005) Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) 179:678-687
46. Wojtowicz J, Yatema M, Wax P (2008) Withdrawal from gamma- hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. Can J Emerg Med 10:69-74
47. Wood DM, Warren-Gash C, Ashraf T, Greene SL, Shather Z, Trivedy C, Clarke S, Rasmey J, Holt DW, Dargan PI (2008) Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gammabutyrolactone (GBL) and 1,4-butanediol (1,4-BD). Q J Med 101:23-29
48. Wood DM, Brailsford AD, Dargan PI (2011) Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 3:417-25
49. Woolverton WL, Rowlett JK, Winger G, Woods JH, Gerak LR, France CP (1999) Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend 54:137-143
50. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344:87-94